Companies Report Earnings with Mixed Outlooks on 03/10/2025

Companies are set to report earnings before market open. Franco-Nevada (FNV) expects EPS of $0.89, a slight decrease. BioNTech (BNTX) forecasts $0.57, a 72% drop. UroGen Pharma (URGN) and Telos (TLS) show similar declines, while Aligos (ALGS) and DarioHealth (DRIO) report increases.

Date: 08-03-2025

AI Rating: 5

Earnings Per Share (EPS)
The report mentions several companies with their projected earnings per share (EPS) leading up to the earnings release date of March 10, 2025. Franco-Nevada Corporation (FNV) forecasts an EPS of $0.89, which is a 1.11% decrease from the previous year. BioNTech SE (BNTX) sees a significant decline, predicting an EPS of $0.57, represented by a drastic 72.20% decrease. UroGen Pharma Ltd. (URGN) anticipates an EPS of -$0.74, also reflecting a 2.78% decrease. Likewise, Telos Corporation (TLS) is expecting an EPS of -$0.21, representing a steep 75.00% decrease. In contrast, Aligos Therapeutics, Inc. (ALGS) forecasts an EPS of -$2.50, marking a 54.55% increase from the same quarter last year. DarioHealth Corp. (DRIO) projects an EPS of -$0.31 with a 24.39% increase compared to last year.

Price to Earnings (P/E) Ratio
The Price to Earnings ratio for Franco-Nevada is 46.17, which is higher than the industry average, indicating possible higher earnings growth compared to competitors. BioNTech shows a negative P/E ratio of -32.41, which raises concerns about earnings viability. UroGen Pharma also has a negative P/E ratio of -3.31, though it is set against an industry average of -4.00. Telos Corporation, with a P/E of -4.25, indicates lower expected earnings performance relative to its sector. In contrast, Aligos has a P/E ratio of -1.30 which is better than the industry’s average, suggesting it may perform better in terms of growth. DarioHealth's P/E ratio of -0.62 also indicates a more favorable position relative to its industry average of 5.00.

Stocks: FNV BNTX URGN TLS ALGS DRIO